Onkologie. 2024:18(2):116-120 | DOI: 10.36290/xon.2024.021

The importance of the microbiome in hematooncology patients

Lucie Dlouhá
I. interní klinika - klinika hematologie, 1. LF a VFN, Praha

The role of particular bacteria such as Helicobacter pylori in the etiology and pathoge­nesis of lymphoma has been well known, but in recent years the importance of the micro­biome complex (made up of 1013 to 1018 microbes that inhabit the human body) has also become apparent. Its effect is mediated by the regulation of the immune system, either by direct action or through produced metabolites. Accumulating data suggest that the composition of the gut microbiota impacts a wide range of disea­ses, inclu­ding cancer. Patients with hematological malignancies often show reduced species diversity and different microbiota composition compared to healthy controls. Some bacteria are also associated with complications or response to treatment. Nowadays, the importance of the microbial effect is increasing, particularly with the wider use of immunotherapy, where the treatment efficacy relays on a functional immune system. In this review, we focus on the role of the gut microbiota in the etiology and pathogenesis of hematological malignancies and its role in impacting anticancer therapy.

Keywords: microbiome, microbiota, hematooncology, cancer.

Accepted: April 19, 2024; Published: May 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dlouhá L. The importance of the microbiome in hematooncology patients. Onkologie. 2024;18(2):116-120. doi: 10.36290/xon.2024.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yue X, Zhou H, Wang S, et al. H. Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease. Cancer Med. 2024 Jan 18. doi: 10.1002/cam4.6799. Epub ahead of print. PMID: 38239049. Go to original source... Go to PubMed...
    2. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141. Go to original source... Go to PubMed...
    3. Masetti R, Zama D, Leardini D, et al. Microbiome-Derived Metabolites in Allogeneic Hematopoietic Stem Cell Transplantation. Int J Mol Sci. 2021;22(3):1197. Go to original source... Go to PubMed...
    4. Manos J. The human microbiome in disease and pathology. APMIS Acta Pathol Microbiol Immunol Scand. 2022;130(12):690-705. Go to original source... Go to PubMed...
    5. Long Y, Tang L, Zhou Y, et al. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. BMC Med. 2023;21(1):66. Go to original source... Go to PubMed...
    6. Zhou L, Zhang M, Wang Y, et al. Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1. Inflamm Bowel Dis. 2018;24(9):1926-1940. Go to original source... Go to PubMed...
    7. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-450. Go to original source... Go to PubMed...
    8. Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80-86. Go to original source... Go to PubMed...
    9. Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, et al. Role of the gut microbiota in hematologic cancer. Front Microbiol. 2023;14:1185787. Go to original source... Go to PubMed...
    10. Huang X, Cai H, Zhao Y, et al. The Gut Microbiome and Acute Leukemia: Implications for Early Diagnostic and New Therapies. Mol Nutr Food Res. 2023;e2300551. Go to original source... Go to PubMed...
    11. Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineo­plastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 2016;5(6):e1150399. Go to original source... Go to PubMed...
    12. Yoon SE, Kang W, Choi S, et al. The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma. Blood. 2023;141(18):2224-2238. Go to original source... Go to PubMed...
    13. Pianko MJ, Devlin SM, Littmann ER, et al. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv. 2019;3(13):2040-2044. Go to original source... Go to PubMed...
    14. Morales ML, Ferrer-Marín F. Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them? Cancers. 2023;15(4):1348. Go to original source... Go to PubMed...
    15. Jiang H, Zhao X, Zang M, et al. Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxid Med Cell Longev. 2022;2022:1482811. Go to original source... Go to PubMed...
    16. Wang R, Yang X, Liu J, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. Nat Commun [Internet]. 2022 [cited 2024 Jan 30];13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085760/. Go to original source...
    17. Khan N, Lindner S, Gomes ALC, et al. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood. 2021;137(11): 1527-1537. Go to original source... Go to PubMed...
    18. Asokan S, Cullin N, Stein-Thoeringer CK, et al. CAR-T Cell Therapy and the Gut Microbiota. Cancers. 2023; 15(3):794. Go to original source... Go to PubMed...
    19. Jiang H, Zhang Q. Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review). Oncol Lett. 2024;27(2):87. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.